View Post

Breast cancer risk among BRCA carriers influenced by timing, number of pregnancies

In In The News by Barbara Jacoby

By: Terry MB, et al. JNCI Cancer Spectr. 2018;doi:10.1093/jncics/pky078. From: healio.com The timing and number of full-term pregnancies appeared to influence the risk for breast cancer among women with BRCA1 or BRCA2 mutations, according to study results published in Journal of the National Cancer Institute Cancer Spectrum. BRCA1 carriers who had only one full-term pregnancy and BRCA2 carriers who had …

View Post

Lynparza, First In Its Class Of Cancer Drugs, Offers Surprisingly Broad Activity

In In The News by Barbara Jacoby

By: Elaine Schattner From: forbes.com ..What’s emerging is that this new class of drugs, once considered of limited benefit and primarily for cancer patients with BRCA mutations, offers a wide range of anti-tumor activity. In December 2014, the FDA approved the first medication of this type, olaparib (brand name: Lynparza, AstraZeneca) for treatment of refractory ovarian cancer. The drug comes …